Federal Register Notice: FDA is reopening the comment period for the notice of availability entitled Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate, published in the 9/10 Federal Register. The agency is reopening the comment period due to the inability of some to submit comments through the www.regulations.gov Web site from 11/4-11/13 due to technical difficulties. To view this notice, click here.
